AI-generated summary
This review examines photobiomodulation therapy as a possible add-on treatment for non-exudative (dry) age-related macular degeneration. The authors report that early animal and human studies suggest the therapy can affect pathways linked to the disease, and that several clinical trials showed improvements in visual and anatomic measures. However, the authors note that these trials are limited by sample size, differences in treatment algorithms, and tested populations, and that further work is needed.
- Who or what was studied
- Patients with non-exudative (dry) age-related macular degeneration
- Limits stated in the abstract
- The authors state that the clinical trials are limited by sample size, differences in treatment algorithm, and populations tested.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on ovid.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Photobiomodulation therapy, Photobiomodulation, Inflammation, Wound healing, Sample size. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.